Applied DNA Sciences Files S-1 Registration Statement

TL;DR

<b>Applied DNA Sciences has filed an S-1 registration statement for a proposed public offering of securities.</b>

AI Summary

APPLIED DNA SCIENCES INC (BNBX) filed a IPO Registration (S-1) with the SEC on March 12, 2024. Applied DNA Sciences, Inc. filed an S-1 registration statement with the SEC on March 12, 2024. The filing indicates the company is incorporated in Delaware with its principal executive offices in Stony Brook, New York. The company's IRS Employer Identification Number is 59-2262718. James A. Hayward, Ph.D., Sc.D. is listed as Chairman, Chief Executive Officer, and President. The filing is for a proposed sale of securities to the public on a delayed or continuous basis.

Why It Matters

For investors and stakeholders tracking APPLIED DNA SCIENCES INC, this filing contains several important signals. This S-1 filing signals Applied DNA Sciences' intent to raise capital through the sale of securities, potentially impacting its financial structure and growth strategy. The registration statement provides detailed information about the company's business, financial condition, and risks, which is crucial for investors considering participation in the offering.

Risk Assessment

Risk Level: medium — APPLIED DNA SCIENCES INC shows moderate risk based on this filing. The company is filing an S-1, which is a registration statement for a public offering. This indicates potential dilution for existing shareholders and the inherent risks associated with new equity offerings.

Analyst Insight

Investors should review the full S-1 filing to understand the specifics of the proposed securities offering and the associated risks before making any investment decisions.

Key Numbers

• S-1 — Form Type (Registration Statement)
• 333-277832 — SEC File Number (Registration Statement)
• 24739629 — Film Number (SEC Filing)
• 0930 — Fiscal Year End (Company Financials)

Key Players & Entities

• Applied DNA Sciences, Inc. (company) — Registrant
• SEC (regulator) — Securities and Exchange Commission
• 20240312 (date) — Filing Date
• Delaware (jurisdiction) — State of incorporation
• Stony Brook, New York (location) — Principal executive offices
• 59-2262718 (identifier) — IRS Employer Identification Number
• James A. Hayward, Ph.D., Sc.D. (person) — Chairman, Chief Executive Officer and President
• Rule 415 (regulation) — Securities Act of 1933

FAQ

Industry Context

Applied DNA Sciences operates in the testing laboratories sector, focusing on providing services related to DNA technologies.

Regulatory Implications

The filing is made under the Securities Act of 1933, which governs the registration of securities offered to the public.

What Investors Should Do

1. Review the full S-1 filing for detailed information on the proposed securities offering.
2. Analyze the company's business model, financial health, and risk factors outlined in the S-1.
3. Assess the potential impact of the offering on existing shareholder equity and dilution.

Key Dates

• 2024-03-12: S-1 Filing — Registration statement filed with the SEC.

Year-Over-Year Comparison

This is a new S-1 filing, so there is no prior filing to compare against for this specific registration event.

Key Financial Figures

• $0.001 — 8,122 shares of common stock, par value $0.001 per share (the &ldquo;Common Stock&rdqu
• $0.609 — Warrant will have an exercise price of $0.609 per share of Common Stock and will beco
• $0.56 — rted sale price of our Common Stock was $0.56 per share. We are a &ldquo;smaller rep
• $1.5 million — acturing facility will be approximately $1.5 million. We anticipate that the proceeds from t
• $7 million — ct, the cost may be up to approximately $7 million which would require additional funding.

Filing Documents

• tm247993d1_s1.htm (S-1) — 438KB
• tm247993d1_ex5-1.htm (EX-5.1) — 10KB
• tm247993d1_ex23-1.htm (EX-23.1) — 3KB
• tm247993d1_ex-filingfees.htm (EX-FILING FEES) — 25KB
• image_001.jpg (GRAPHIC) — 3KB
• tm247993d1_s1img001.jpg (GRAPHIC) — 3KB
• tm247993d1_s1img002.jpg (GRAPHIC) — 3KB
• tm247993d1_s1img003.jpg (GRAPHIC) — 5KB
• 0001104659-24-033115.txt (&nbsp;) — 497KB

From the Filing

As filed with the Securities and Exchange Commission on March 11, 2024. Registration Statement No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Applied DNA Sciences, Inc. (Exact name of Registrant as specified in its charter) Delaware 7380 59-2262718 (State or other jurisdiction of incorporation or organization) (Primary Standard Industrial Classification Code Number) (I.R.S. Employer Identification Number) 50 Health Sciences Drive Stony Brook, New York 11790 631-240-8800 (Address, including zip code, and telephone number, including area code, of Registrant&rsquo;s principal executive offices) James A. Hayward, Ph.D., Sc.D. Chairman, Chief Executive Officer and President Applied DNA Sciences, Inc. 50 Health Sciences Drive Stony Brook, New York 11790 631-240-8801 (Name, address, including zip code, and telephone number, including area code, of agent for service) Copies to: Merrill M. Kraines Todd Kornfeld McDermott Will & Emery LLP One Vanderbilt Avenue New York, New York 10017-3852 (212) 547-5616 Approximate date of commencement of proposed sale to the public: From time to time after this Registration Statement becomes effective. If any of the securities being registered on this form are to be offered on a delayed or continuous basis pursuant to Rule 415 under the Securities Act of 1933, check the following box. If this form is filed to register additional securities for an offering pursuant to Rule 462(b) under the Securities Act, please check the following box and list the Securities Act registration If this form is a post-effective amendment filed pursuant to Rule 462(c) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration If this form is a post-effective amendment filed pursuant to Rule 462(d) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration Indicate by check mark whether the registrant is a large accelerated &ldquo;large accelerated filer,&rdquo; &ldquo;accelerated filer,&rdquo; &ldquo;smaller reporting company,&rdquo; and &ldquo;emerging growth company&rdquo; in Rule 12b-2 of the Exchange Act. Large accelerated filer Accelerated filer Non-accelerated filer Smaller reporting company Emerging growth company If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. The Registrant hereby amends this Registration specifically states that this Registration Statement shall thereafter become effective in accordance with Section 8(a) of the Securities Act of 1933, as amended, or until the Registration Statement shall become effective on such date as the Securities and Exchange Commission, acting pursuant to said Section 8(a), may determine. The information contained in this prospectus is not complete and may be changed. The selling stockholders named in this prospectus may not sell these securities until the registration we are not soliciting offers to buy these securities in any jurisdiction where such offer or sale is not permitted. PRELIMINARY PROSPECTUS DATED MARCH 11, 2024 Up to 11,288,122 shares of Common Stock underlying the Common Warrants Applied DNA Sciences, Inc. This prospectus relates to the resale from time to time, by the selling stockholders (the &ldquo;Selling Stockholders&rdquo;) identified in this prospectus under the caption &ldquo;Selling Stockholders,&rdquo; of up to 11,288,122 shares of common stock, par value $0.001 per share (the &ldquo;Common Stock&rdquo;), which the selling stockholders may acquire upon the exercise of outstanding warrants (the &ldquo;Common Warrants&rdquo;). We issued the Common Warrants to the Selling Stockholders in a private placement concurrent with a registered direct offering (the &ldquo;Offering&rdquo;) of 3,228,056 shares of Common Stock and pre-funded warrants (the &ldquo;Pre-Funded Warrants&rdquo;) to purchase 2,416,005 shares of Common Stock. Each Common Warrant will have an exercise price of $0.609 per share of Common Stock and will become exercisable upon Shareholder Approval. &ldquo;Shareholder Approval&rdquo; means the first trading day after the filing of a Form 8-K disclosing the approval pursuant to the applicable rules and regulations of The Nasdaq Capital Market (&ldquo;Nasdaq&rdquo;) from the shareholders of the Company with respect to the issuance of all of the shares underlying the Common Warrants and the reduction in exercise price and extension of expiration dates of the Warrants described in &ldquo;Warrant Repricing&rdquo; beginning on page 16. The Commo

View Full Filing

View this S-1 filing on SEC EDGAR